RT Journal Article
T1 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
A1 González Bayón, Luis Andrés
A1 Steiner, M.A.
A1 Vásquez Jiménez, W.
A1 Asencio Pascual, José Manuel
A1 Álvarez de la Sierra, P.
A1 Atahualpa Arenas, F.
A1 Rodríguez del Campo, J.
A1 García Sabrido, José Luis
AB AimCytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) has been proposed as treatment for advanced epithelial ovarian carcinoma (EOC). No consensus exists on when to administer CRS + HIPEC during the natural history of the disease, namely, as upfront therapy, at first recurrence, or at second or subsequent recurrence.Patients and methodsWe analyzed a series of patients with advanced EOC collected prospectively in an institution with a peritoneal malignant disease treatment program. Patients were treated with CRS + HIPEC upfront, at first recurrence, and at second or subsequent recurrence.ResultsWe treated 42 patients: 15 upfront, 19 at first recurrence, and 8 at second or subsequent recurrence. Cytoreduction was complete (CC0) in 75% of cases; residual disease was <2.5 mm (CC1) in 25%. Severe morbidity (CTCAE v.3.0, grade 3–4) was 26%, and hospital mortality was 7%. After a median follow-up of 24 months, median overall survival was 77.8 months for patients treated upfront, 62.8 months for patients treated at first recurrence, and 35.7 months for patients treated at second or subsequent recurrence. Disease-free survival was 21.1 months, 18 months, and 5.7 months, respectively. Overall survival in the upfront and first recurrence groups was similar, and statistically significant differences with the second recurrence group were identified (p < 0.03).ConclusionsTreatment of advanced EOC using CRS + HIPEC is promising in terms of overall survival and disease-free survival when administered as upfront and at first recurrence therapy. These results warrant further evaluation in a randomized trial.
PB Elsevier
SN 0748-7983
YR 2013
FD 2013-07-17
LK https://hdl.handle.net/20.500.14352/124989
UL https://hdl.handle.net/20.500.14352/124989
LA eng
NO L. Gonzalez Bayon, M.A. Steiner, W. Vasquez Jimenez, J.M. Asencio, P. Alvarez de Sierra, F. Atahualpa Arenas, J. Rodriguez del Campo, J.L. Garcia Sabrido, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: Upfront therapy, at first recurrence, or later?, European Journal of Surgical Oncology (EJSO), Volume 39, Issue 10, 2013, Pages 1109-1115, ISSN 0748-7983, https://doi.org/10.1016/j.ejso.2013.06.022.
DS Docta Complutense
RD 19 mar 2026